


SUPPLEMENTARY APPENDIX

Supplementary Table 1 Most commonly reported treatment-related TEAEs


Treatment-related TEAE, n (%)	LBCL N = 157	DLBCL + HGBCL N = 148	DLBCL (N = 139)
Cytokine release syndrome	80 (51)	75 (51)	69 (50)
Fatigue	22 (14)	21 (14)	21 (15)
Pyrexia	16 (10)	15 (10)	14 (10)
Neutropenia	30 (19)	28 (19)	28 (20)
Diarrhea	10 (6)	10 (7)	10 (7)
Nausea	12 (8)	11 (7)	11 (8)
Anemia	10 (6)	10 (7)	9 (7)
COVID-19	4 (3)	4 (3)	4 (3)
Injection-site reaction	31 (20)	30 (20)	29 (21)

COVID-19, coronavirus disease 2019; *DLBCL*, diffuse large B-cell lymphoma; *HGBCL*, high-grade B-cell lymphoma; *LBCL*, large B-cell lymphoma; *TEAE*, treatment-emergent adverse event

a




b




Supplementary Fig. 1 PFS (a) and OS (b) in the overall population

CI, confidence interval; DLBCL, diffuse large B-cell lymphoma; HGBCL, high-grade B-cell lymphoma; LBCL, large B-cell lymphoma; OS, overall survival; PFS, progression-free survival




Supplementary Fig. 2 Kaplan–Meier PFS curve with 30- and 36-month PFS estimates by MRD status in MRD-evaluable patients from the overall population

C, cycle; D, day; MRD, minimal residual disease; PFS, progression-free survival



Supplementary Fig. 3 Rates of grade ≥ 3 infections by analysis intervals (up to week 144)



Supplementary Fig. 4 Rates of grade ≥ 3 cytopenias by analysis intervals (up to week 144)